These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26553682)

  • 61. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.
    Findlow J; Bai X; Findlow H; Newton E; Kaczmarski E; Miller E; Borrow R
    Vaccine; 2015 Jun; 33(29):3322-30. PubMed ID: 26025807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial.
    P Safadi MA; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Apr; 35(16):2052-2059. PubMed ID: 28318767
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt.
    Sundaram ME; Wolfson J; Osterholm M; Sow S; Ansah PO; Diallo A; Cusick SE
    Vaccine; 2020 Dec; 38(52):8351-8356. PubMed ID: 33223309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
    Borja-Tabora C; Montalban C; Memish ZA; Van der Wielen M; Bianco V; Boutriau D; Miller J
    BMC Infect Dis; 2013 Mar; 13():116. PubMed ID: 23510357
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.
    Al-Mazrou Y; Khalil M; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
    Clin Vaccine Immunol; 2012 Jul; 19(7):999-1004. PubMed ID: 22552602
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.
    Sherman AC; Stephens DS
    Expert Rev Vaccines; 2020 May; 19(5):455-463. PubMed ID: 32321332
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.
    Tang Y; Plikaytis BD; Preziosi MP; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S531-9. PubMed ID: 26553685
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.
    Hodgson A; Forgor AA; Chandramohan D; Reed Z; Binka F; Bevilacqua C; Boutriau D; Greenwood B
    PLoS One; 2008 May; 3(5):e2159. PubMed ID: 18478093
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali.
    Basta NE; Borrow R; Berthe A; Onwuchekwa U; Dembélé AT; Almond R; Frankland S; Patel S; Wood D; Nascimento M; Manigart O; Trotter CL; Greenwood B; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S578-85. PubMed ID: 26553691
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology.
    Pöllabauer EM; Petermann R; Ehrlich HJ
    Hum Vaccin; 2005; 1(4):131-9. PubMed ID: 17012872
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
    Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
    Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
    Findlow H; Borrow R
    Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.